within Pharmacolibrary.Drugs.ATC.N;

model N03AC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Paramethadione is an oxazolidinedione anticonvulsant primarily used historically for the treatment of absence (petit mal) seizures. It is chemically related to trimethadione. Due to safety concerns, especially severe adverse effects including hematological toxicity and teratogenicity, its clinical use has been largely discontinued and it is no longer approved or widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult population, oral administration, no published specific human pharmacokinetic studies available.</p><h4>References</h4><ol><li><p>Tanaka, E, et al., &amp; Takabatake, E (1981). Pharmacokinetic studies of trimethadione and its metabolite in rats with chemical-induced liver injury. <i>Journal of pharmacobio-dynamics</i> 4(8) 576–583. DOI:<a href=&quot;https://doi.org/10.1248/bpb1978.4.576&quot;>10.1248/bpb1978.4.576</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7299621/&quot;>https://pubmed.ncbi.nlm.nih.gov/7299621</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AC01;
